openPR Logo
Press release

Award-Winning CHR Paper Gives Hope to IVF Patients with Low AMH Levels

06-11-2012 09:08 PM CET | Health & Medicine

Press release from: Center for Human Reproduction

Award-Winning CHR Paper Gives Hope to IVF Patients with Low AMH

A recent paper(1) by researchers at the Center for Human Reproduction (CHR) in New York City – which describes reasonable live birth chances in women with extremely low ovarian reserve – received the prestigious Austrian Hugo Husslein Prize. The prize is awarded biannually by the Austrian Society of Obstetrics and Gynecology.

The paper, published in the journal Human Reproduction, reports on the “moderate but reasonable” live birth chances in women with extremely low ovarian reserve, demonstrated by either completely undetectable or very low anti-Müllerian hormone (AMH) levels. Women in the study were also older, with mean age approaching 41. Despite these poor prognostic indicators, the authors were able to establish clinical pregnancies in 15.6% of these women.

“With extremely low serum AMH levels, moderate but reasonable pregnancy and live birth rates are still possible. Extremely low AMH levels do not appear to represent an appropriate marker for withholding fertility treatment,” concluded the paper.

Based on CHR’s protocol, women in the study received DHEA supplementation prior to starting their IVF cycles. While the result of this study may not be applicable to women without DHEA supplementation, the results brings hope to women struggling to achieve pregnancy after 40, as well as to younger women with premature ovarian aging (POA).

“It was a great honor to receive the prize,” says Andrea Weghofer, MD, Associate Professor of Obstetrics and Gynecology, Medical University Vienna – a Visiting Associate Scientist at CHR and lead author of the study. She continues: “but the real honor was in demonstrating that these women, who are likely to be turned away by most fertility centers based on poor prognosis, can still be helped with their own eggs with reasonable success rates.”

“This really echoes our philosophy at CHR,” adds Norbert Gleicher, MD, Medical Director and Chief Scientist of CHR. “We never turn away patients who fully understand their limited chances, and our entire clinical team literally fights for every egg and every embryo.”

CHR, over the years, has made many breakthroughs in treating women with poor prognosis, who failed at other centers or have been refused treatments because of presumed small chances. The center’s IVF success rates in such patients have been improving year to year, reaching another record height in 2011.

(1)Weghofer A, Dietrich W, Barad DH, Gleicher N. Live birth chances in women with extremely low serum anti-Müllerian hormone levels. Hum Reprod 2011;26(7):1905-9.

About Center for Human Reproduction
The Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com/), is one of the world’s leading fertility centers in New York City with international patient following. CHR has a worldwide reputation as the "fertility center of last resort," specializing in treatment of infertility in women with diminished ovarian reserve due to advanced age or due to premature ovarian aging (POA). Dr. Weghofer and Dr. Gleicher are available for further comments.

Communications Manager
Center for Human Reproduction
212-994-4400 x.4491
21 E. 69th Street
New York, NY 10021
webadmin@thechr.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Award-Winning CHR Paper Gives Hope to IVF Patients with Low AMH Levels here

News-ID: 225066 • Views:

More Releases from Center for Human Reproduction

IVF Success Rates Not Improved by Preimplantation Genetic Screening, According to CHR Research
IVF Success Rates Not Improved by Preimplantation Genetic Screening, According t …
There is no evidence that recent technical improvements in preimplantation genetic screening (PGS) improve IVF pregnancy chances, according to a paper just published online in the Journal of Assisted Reproduction and Genetics1. The review, by two fertility specialists from New York’s Center for Human Reproduction (CHR), raises important questions, as this “new” PGS is actively marketed to patients as “proven” and “established” to increase IVF success rates. In the late ‘90s,
Research from CHR Offers Hope for Women with Treatment-Resistant Thin Endometrium
Research from CHR Offers Hope for Women with Treatment-Resistant Thin Endometriu …
November 15, 2012 (New York, NY) – Direct perfusion of the endometrial cavity with granulocyte colony-stimulating factor (G-CSF) improves the thickness of the endometrial lining in IVF patients with too thin endometrium even after treatments, according to a new study just published online in the medical journal Human Reproduction(1). In the study, 21 women undergoing in vitro fertilization (IVF) cycles at the Center for Human Reproduction (CHR) in New York City
FMR1 Gene May Control Women’s Fertility Life Cycle, According to Research
FMR1 Gene May Control Women’s Fertility Life Cycle, According to Research
October 23, 2012 (New York, NY) – A new study presented at the Annual Meeting of the American Society for Reproductive Medicine (ASRM) in San Diego, CA, offers further evidence that the fragile X mental retardation 1 gene (FMR1 gene) may play an important role in controlling women’s fertility life cycles. The study, conducted by researchers from the Center for Human Reproduction (CHR), a leading fertility center in New York
BRCA1/2 Mutation and FMR1 Gene Study Has Potential Implications for Cancer Screening and Treatment
BRCA1/2 Mutation and FMR1 Gene Study Has Potential Implications for Cancer Scree …
BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria. BRCA1/2-positive embryos will only survive when also carrying a specific FMR1 gene genotype. In a paper

All 4 Releases


More Releases for CHR

Gut Microbiota Supplement Market to Witness Huge Growth by 2031 - Nestlé S.A, C …
DataM Intelligence has published a new research report on "Gut Microbiota Supplement Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF
Microecological Preparation Market | BioGaia, Biosearch Life, China-Biotics, Chr …
The global microecological preparation market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the microecological preparation market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the
Bifidobacterium Market Size | Industry Report, 2027|Chr Hansen, DSM, Yakult
LOS ANGELES, United States: The report is an all-inclusive research study of the global Bifidobacterium market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Bifidobacterium market with the help of research methodologies such as PESTLE and Porter’s Five Forces analysis. They have provided accurate and reliable market data and useful recommendations to help
Compound Lipase Market Foreseen to Grow Exponentially by 2028 | DSM BioSolutions …
This detailed market study covers compound lipase market growth potentials which can assist the stake holders to understand key trends and prospects in compound lipase market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The
Global Probiotics Market 2019 - DuPont (Danisco), Chr. Hansen, Lallemand, China- …
This new report by Eon Market Research, titled “Global Probiotics Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Probiotics industry at a global as well as regional and country level. Key facts analyzed in this report include the Probiotics market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive
Carotenoids Market – Sophisticated Performance 2025 | Farbest Brands, Chr. Han …
Global Carotenoids Market: Overview Carotenoids, a class of phytonutrients, are plant pigments due to which several fruits and vegetables acquire their bright shades of red, orange, and yellow. Several algae, bacteria, and plants contain these pigments. Acting as anti-oxidants, carotenoids possess cancer-fighting properties, suggests recent research. Carotenoids also have anti-inflammatory properties, improve the immune system, and are believed to aid in the prevention of cardiovascular diseases. Some of the fruits and